initial safety results for phase 2 magnetismm-3 trial presented at asco 2022
Published 2 years ago • 763 plays • Length 8:33Download video MP4
Download video MP3
Similar videos
-
9:14
efficacy and safety of elranatamab in pts with relapsed/refractory multiple myeloma: magnetismm-3
-
11:22
updated efficacy/safety results of majestec-1 (teclistamab) at asco 2022
-
10:16
top multiple myeloma abstracts presented at asco and eha 2022
-
7:06
efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
-
4:20
what were the results of the determination trial presented at asco and eha?
-
5:53
phase 1 study of car t-ddbcma in rrmm presented at asco 2022
-
1:04:22
imwg conference series: asco & eha 2022
-
6:10
updated phase1b results for talquetamab in combination with daratumumab
-
59:53
clinical trials in multiple myeloma
-
1:03:56
top myeloma research presented at asco & eha
-
9:56
ide-cel vs standard regimens for high-risk multiple myeloma: karmma-3 analysis | asco 2023
-
58:19
sequencing bcma myeloma therapies
-
7:00
elranatamab induces durable responses for patients with relapsed or refractory multiple myeloma
-
10:57
linker-mm1 study: linvoseltamab (regn5458) in patients with rr multiple myeloma | asco 2023
-
1:03:05
the international myeloma foundation's imwg conference series: making sense of treatment 2021
-
8:12
evaluating teclistamab in relapsed and/or refractory multiple myeloma
-
1:02:01
top myeloma research presented at asco & eha 2024
-
0:54
aims & design of the excaliber-rrm study
-
3:03:13
imf patient & family webinar - new frontiers in myeloma care